INSMED Inc: directors' dealings · United States · SEC (Form 4)

About INSMED Inc

Insmed Inc. (NASDAQ: INSM) is a U.S.-based biopharmaceutical company headquartered in Bridgewater, New Jersey, in the United States. Founded in 1988, the company has evolved from an earlier-stage developer into a focused respiratory-disease platform spanning marketed products and an active late-stage pipeline. For French-speaking investors in France, Belgium, and Switzerland, Insmed is best understood as a growth-oriented specialty pharma/biotech company: it already has commercial assets, but a significant part of its equity story still depends on clinical execution and regulatory expansion. The company’s current business is centered on two key products. ARIKAYCE, an inhaled liposomal amikacin product, remains an important commercial franchise and is approved in the United States, Europe, and Japan for patients with MAC lung disease who remain culture-positive after prior multidrug therapy. BRINSUPRI (brensocatib), which received U.S. approval in 2025 and European Commission approval later the same year, is now the company’s most important growth driver. BRINSUPRI is a once-daily oral DPP1 inhibitor for non-cystic fibrosis bronchiectasis, a serious chronic lung disease with historically limited approved treatment options. That approval meaningfully broadens Insmed’s commercial runway and reduces reliance on a single legacy asset over time. Insmed’s competitive position is built on deep expertise in pulmonary and orphan-disease development, especially in areas of high unmet medical need. The company has combined regulatory know-how, clinical development capability, and international commercialization infrastructure. Beyond its marketed portfolio, Insmed is advancing several pipeline programs, including treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, plus additional early-stage initiatives. Recent corporate updates indicate a busy clinical calendar and a strategy aimed at expanding the addressable market beyond bronchiectasis and MAC lung disease. Geographically, Insmed remains firmly anchored in the United States, with its global headquarters in Bridgewater, New Jersey, but it also maintains offices and research sites across Europe and in Japan. That footprint supports global regulatory filings, regional launches, and longer-term international growth. Recent major milestones include the FDA approval of BRINSUPRI in 2025, the European Union approval in 2025, and positive topline data for TPIP. From an investor’s perspective, Insmed on NASDAQ in the United States offers a combination of commercial momentum, multiple clinical catalysts, and international expansion potential, alongside the usual biotech risks tied to trial outcomes, pricing, reimbursement, and execution.